wheal

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

211 Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.+: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750. IF: 5.42

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Read More »

Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency

This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Devel- opment and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded

Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency Read More »

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

310 Zuberbier, T.+, Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer-Weber, B., Bernstein, J. A., Bindslev-Jensen, C., Brzoza, Z., Buense Bedrikow, R., Canonica, G. W., Church, M. K., Craig, T., Danilycheva, I. V., Dressler, C., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Katelaris, C. H., Kocatürk, E., Kulthanan, K., Larenas-Linnemann, D., Leslie, T. A., Magerl, M., Mathelier-Fusade, P., Meshkova, R. Y., Metz, M., Nast, A., Nettis, E., Oude-Elberink, H., Rosumeck, S., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Vestergaard, C., Wedi, B., Werner, R. N., Zhao, Z., and Maurer, M.: The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy 2018: 73; 1393-1414. IF: 6.77

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria Read More »

Methods report on the development of the 2013 revision and update of the EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria

185 Zuberbier, T.+, Aberer, W., Asero, R., Bindslev-Jensen, C. Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Abdul Latiff, A. H., Mathelier-Fusade, P., Metz, M., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier P., Simons, F. E., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Wedi, B., Zhu, X. J., Nast, A., and Maurer, M.: Methods report on the development of the 2013 revision and update of the EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2014: 69; e1-e29. IF: 6.03

o.185

Methods report on the development of the 2013 revision and update of the EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria Read More »

The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update

184 Zuberbier, T.+, Aberer, W., Asero, R., Bindslev-Jensen, C., Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Abdul Latiff, A. H., Mathelier-Fusade, P., Metz, M., Nast, A., Saini, S. S., Sánches-Borges, M., Schmidt-Grendelmeier, P., Simons, F. E. R., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Wedi, B., Zhu, X. J., and Maurer, M.: The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. Allergy 2014: 69; 868-887. IF: 6.03

The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update Read More »

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

163 Kaplan, A., Ledford, D., Ashby, M., Canvin, J, Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., Stirling, R. G., Kuna, P., Berger, W., Maurer, M. and Rosén, K.+: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J. Allergy Clin. Immunol. 2013: 132; 101-109. IF: 11.25

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Read More »

Therapy of urticaria: German language version of the international S3-guideline

138 Zuberbier, T.+, Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Maurer, M. Merk, H. F., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., and Wedi, B.: Therapy of urticaria: German language version of the international S3-guideline. Allergologie 2012: 4; 187-208. IF 0.33

Therapy of urticaria: German language version of the international S3-guideline Read More »